-
2
-
-
33645526144
-
Cancer statistics, 2006
-
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-30
-
(2006)
CA Cancer J Clin
, vol.56
, pp. 106-130
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
-
3
-
-
0033614446
-
Chronic myeloid leukemia
-
Apr 29;
-
Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999 Apr 29; 340 (17): 1330-40
-
(1999)
N Engl J Med
, vol.340
, Issue.17
, pp. 1330-1340
-
-
Sawyers, C.L.1
-
4
-
-
33745114173
-
AMN107 (nilotinib): A novel and selective inhibitor of BCR-ABL
-
Jun 19;
-
Weisberg E, Manley P, Mestan J, et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006 Jun 19; 94 (12): 1765-9
-
(2006)
Br J Cancer
, vol.94
, Issue.12
, pp. 1765-1769
-
-
Weisberg, E.1
Manley, P.2
Mestan, J.3
-
5
-
-
13844251975
-
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
-
Feb;
-
Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005 Feb; 7 (2): 129-41
-
(2005)
Cancer Cell
, vol.7
, Issue.2
, pp. 129-141
-
-
Weisberg, E.1
Manley, P.W.2
Breitenstein, W.3
-
6
-
-
0041466445
-
Specific targeted therapy of chronic myelogenous leukemia with imatinib
-
Deininger MWN, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003; 55 (3): 401-23
-
(2003)
Pharmacol Rev
, vol.55
, Issue.3
, pp. 401-423
-
-
Deininger, M.W.N.1
Druker, B.J.2
-
7
-
-
33845444046
-
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
-
Dec 7;
-
Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006 Dec 7; 355 (23): 2408-17
-
(2006)
N Engl J Med
, vol.355
, Issue.23
, pp. 2408-2417
-
-
Druker, B.J.1
Guilhot, F.2
O'Brien, S.G.3
-
8
-
-
33847057304
-
Imatinib: A review of its use in chronic myeloid leukaemia
-
Moen MD, McKeage K, Plosker GL, et al. Imatinib: a review of its use in chronic myeloid leukaemia. Drugs 2007; 67 (2): 299-320
-
(2007)
Drugs
, vol.67
, Issue.2
, pp. 299-320
-
-
Moen, M.D.1
McKeage, K.2
Plosker, G.L.3
-
9
-
-
16844372957
-
Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials [abstract no. 23]
-
Nov 16;
-
Silver RT, Talpaz M, Sawyers CL, et al. Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials [abstract no. 23]. Blood 2004 Nov 16; 104 (11 Pt 1): 11a
-
(2004)
Blood
, vol.104
, Issue.11 PART 1
-
-
Silver, R.T.1
Talpaz, M.2
Sawyers, C.L.3
-
10
-
-
31344472945
-
Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)
-
Feb;
-
Walz C, Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 2006 Feb; 57 (2): 145-64
-
(2006)
Crit Rev Oncol Hematol
, vol.57
, Issue.2
, pp. 145-164
-
-
Walz, C.1
Sattler, M.2
-
11
-
-
33745081606
-
Circumventing resistance to kinase-inhibitor therapy
-
Jun 15;
-
Druker BJ. Circumventing resistance to kinase-inhibitor therapy. N Engl J Med 2006 Jun 15; 354 (24): 2594-6
-
(2006)
N Engl J Med
, vol.354
, Issue.24
, pp. 2594-2596
-
-
Druker, B.J.1
-
12
-
-
21144451094
-
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
-
Jun 1;
-
O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005 Jun 1; 65 (11): 4500-5
-
(2005)
Cancer Res
, vol.65
, Issue.11
, pp. 4500-4505
-
-
O'Hare, T.1
Walters, D.K.2
Stoffregen, E.P.3
-
13
-
-
0034161460
-
Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
-
Mar 1;
-
le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000 Mar 1; 95 (5): 1758-66
-
(2000)
Blood
, vol.95
, Issue.5
, pp. 1758-1766
-
-
le Coutre, P.1
Tassi, E.2
Varella-Garcia, M.3
-
14
-
-
0036850514
-
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
-
Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190-6
-
(2002)
Leukemia
, vol.16
, pp. 2190-2196
-
-
Hochhaus, A.1
Kreil, S.2
Corbin, A.S.3
-
15
-
-
34248204301
-
-
Jabbour E, Cortes J, Kantarjian H. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias [published erratum appears in Expert Opin Investig Drugs 2007 Jul; 16 (7): 1135]. Expert Opin Investig Drugs 2007 May; 16 (5): 679-87
-
Jabbour E, Cortes J, Kantarjian H. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias [published erratum appears in Expert Opin Investig Drugs 2007 Jul; 16 (7): 1135]. Expert Opin Investig Drugs 2007 May; 16 (5): 679-87
-
-
-
-
16
-
-
33745102555
-
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
-
Jun 15;
-
Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006 Jun 15; 354 (24): 2531-41
-
(2006)
N Engl J Med
, vol.354
, Issue.24
, pp. 2531-2541
-
-
Talpaz, M.1
Shah, N.P.2
Kantarjian, H.3
-
17
-
-
33947280081
-
Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy
-
Mar 15;
-
Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007 Mar 15; 109 (6): 2303-9
-
(2007)
Blood
, vol.109
, Issue.6
, pp. 2303-2309
-
-
Hochhaus, A.1
Kantarjian, H.M.2
Baccarani, M.3
-
18
-
-
34248324467
-
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase
-
May 15;
-
Guilhot F, Apperley J, Kim D-W, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007 May 15; 109 (10): 4143-50
-
(2007)
Blood
, vol.109
, Issue.10
, pp. 4143-4150
-
-
Guilhot, F.1
Apperley, J.2
Kim, D.-W.3
-
19
-
-
33947356135
-
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis
-
Apr 15;
-
Cortes J, Rousselot P, Kim D-W, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007 Apr 15; 109 (8): 3207-13
-
(2007)
Blood
, vol.109
, Issue.8
, pp. 3207-3213
-
-
Cortes, J.1
Rousselot, P.2
Kim, D.-W.3
-
20
-
-
24644464172
-
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells
-
Sep 15;
-
Verstovsek S, Golemovic M, Kantarjian H, et al. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 2005 Sep 15; 104 (6): 1230-6
-
(2005)
Cancer
, vol.104
, Issue.6
, pp. 1230-1236
-
-
Verstovsek, S.1
Golemovic, M.2
Kantarjian, H.3
-
21
-
-
24644435728
-
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia
-
Jul 1;
-
Golemovic M, Verstovsek S, Giles F, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 2005 Jul 1; 11 (13): 4941-7
-
(2005)
Clin Cancer Res
, vol.11
, Issue.13
, pp. 4941-4947
-
-
Golemovic, M.1
Verstovsek, S.2
Giles, F.3
-
22
-
-
33745089491
-
AMN107: Inhibitory profile against non-mutated and mutated forms of the Bcr-Abl tyrosine kinase
-
abstract no. 5985, Presented at the, Apr 16-20; Anaheim CA
-
Manley PW, Mestan J, Cowan-Jacob S, et al. AMN107: inhibitory profile against non-mutated and mutated forms of the Bcr-Abl tyrosine kinase [abstract no. 5985]. Presented at the 96th Annual Meeting of the American Association for Cancer Research; 2005 Apr 16-20; Anaheim (CA)
-
(2005)
96th Annual Meeting of the American Association for Cancer Research
-
-
Manley, P.W.1
Mestan, J.2
Cowan-Jacob, S.3
-
23
-
-
40349088801
-
Response dynamics to nilotinib depend on the type of BCR-ABL mutations in patients with chronic myelogenous leukemia (CML) after imatinib failure [abstract no. 7024]
-
Jun 1-5; Chicago IL
-
Mueller MC, Branford S, Radich J, et al. Response dynamics to nilotinib depend on the type of BCR-ABL mutations in patients with chronic myelogenous leukemia (CML) after imatinib failure [abstract no. 7024]. Plus poster presented at the 43rd Annual Meeting of the American Society of Clinical Oncology; 2007 Jun 1-5; Chicago (IL)
-
(2007)
Plus poster presented at the 43rd Annual Meeting of the American Society of Clinical Oncology
-
-
Mueller, M.C.1
Branford, S.2
Radich, J.3
-
24
-
-
33745086350
-
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
-
Jun 15;
-
Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006 Jun 15; 354 (24): 2542-51
-
(2006)
N Engl J Med
, vol.354
, Issue.24
, pp. 2542-2551
-
-
Kantarjian, H.1
Giles, F.2
Wunderle, L.3
-
25
-
-
40349087099
-
-
Kagan M, Tran P, Fischer V, et al. Safety, pharmacokinetics, metabolism, and mass balance of [14C]-AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl tyrosine kinase, in healthy subjects [abstract no. 4887]. Blood 2005 Nov 16; 106 (11 Pt 2): 302b
-
Kagan M, Tran P, Fischer V, et al. Safety, pharmacokinetics, metabolism, and mass balance of [14C]-AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl tyrosine kinase, in healthy subjects [abstract no. 4887]. Blood 2005 Nov 16; 106 (11 Pt 2): 302b
-
-
-
-
26
-
-
57749174353
-
Clinical pharmacokinetics (PK) of AMN107, a novel inhibitor of Bcr-Abl, in healthy subjects and patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) or relapsed/refractory Ph+ acute lymphocytic leukemia (Ph+ ALL) [abstract no. 3095]
-
Jun 20; , 144s
-
Tanaka C, Smith T, Kantarjian H, et al. Clinical pharmacokinetics (PK) of AMN107, a novel inhibitor of Bcr-Abl, in healthy subjects and patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) or relapsed/refractory Ph+ acute lymphocytic leukemia (Ph+ ALL) [abstract no. 3095]. J Clin Oncol 2006 Jun 20; (18 Pt 1 Suppl. 24): 144s
-
(2006)
J Clin Oncol
, Issue.18 PART 1 SUPPL. 24
-
-
Tanaka, C.1
Smith, T.2
Kantarjian, H.3
-
27
-
-
40349085592
-
-
Novartis Pharmaceuticals Corporation:, US prescribing information [online, Available from URL:, Accessed 2007 Nov 29
-
Novartis Pharmaceuticals Corporation: East Hanover (NJ). Tasigna® (nilotinib capsules): US prescribing information [online]. Available from URL: http://www.fda.gov/ [Accessed 2007 Nov 29]
-
Tasigna® (nilotinib capsules)
-
-
East Hanover, N.J.1
-
28
-
-
36348968931
-
Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
-
Nov 15;
-
Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007 Nov 15; 110 (10): 3540-6
-
(2007)
Blood
, vol.110
, Issue.10
, pp. 3540-3546
-
-
Kantarjian, H.M.1
Giles, F.2
Gattermann, N.3
-
29
-
-
41349083969
-
-
le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhib-itor, is active in patients with imatinib-resistant or -intolerant accelerated phase chronic myelogenous leukemia. Blood 2008 Feb 15; 111 (4): 1834-9
-
le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhib-itor, is active in patients with imatinib-resistant or -intolerant accelerated phase chronic myelogenous leukemia. Blood 2008 Feb 15; 111 (4): 1834-9
-
-
-
-
30
-
-
37349112422
-
Nilotinib monotherapy in patients with imatinib-resistant or -intolerant Ph+ chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL)
-
abstract no. 0556, Jun 7-10; Vienna
-
Ottmann O, Larson R, Kantarjian H, et al. Nilotinib monotherapy in patients with imatinib-resistant or -intolerant Ph+ chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL) [abstract no. 0556]. Plus poster presented at the 12th Congress of the European Hematology Association (EHA); 2007 Jun 7-10; Vienna
-
(2007)
Plus poster presented at the 12th Congress of the European Hematology Association (EHA)
-
-
Ottmann, O.1
Larson, R.2
Kantarjian, H.3
-
31
-
-
40349087097
-
Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intoler-ant chronic phase and accelerated phase Philadelphia-positive chronic myelogenous leukemia
-
abstract no. 0554, Jun 7-10; Vienna
-
Giles F, le Coutre P, Bhalla K, et al. Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intoler-ant chronic phase and accelerated phase Philadelphia-positive chronic myelogenous leukemia [abstract no. 0554]. Plus poster presented at the 12th Congress of the European Hematology Association (EHA); 2007 Jun 7-10; Vienna
-
(2007)
Plus poster presented at the 12th Congress of the European Hematology Association (EHA)
-
-
Giles, F.1
le Coutre, P.2
Bhalla, K.3
-
32
-
-
40349098026
-
A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib
-
abstract no. 7038, Jun 1-5; Chicago IL
-
Giles FJ, le Coutre P, Bhalla K, et al. A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib [abstract no. 7038]. Plus poster presented at the 43rd Annual Meeting of the American Society of Clinical Oncology; 2007 Jun 1-5; Chicago (IL)
-
(2007)
Plus poster presented at the 43rd Annual Meeting of the American Society of Clinical Oncology
-
-
Giles, F.J.1
le Coutre, P.2
Bhalla, K.3
-
33
-
-
0037092980
-
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase
-
May 15;
-
Kantarjian HM, Cortes J, O'Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002 May 15; 99 (10): 3547-53
-
(2002)
Blood
, vol.99
, Issue.10
, pp. 3547-3553
-
-
Kantarjian, H.M.1
Cortes, J.2
O'Brien, S.3
-
34
-
-
0037186915
-
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
-
Feb 28;
-
Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002 Feb 28; 346 (9): 645-52
-
(2002)
N Engl J Med
, vol.346
, Issue.9
, pp. 645-652
-
-
Kantarjian, H.1
Sawyers, C.2
Hochhaus, A.3
-
35
-
-
35648936586
-
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia
-
Nov;
-
Singer JB, Shou Y, Giles F, et al. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia 2007 Nov; 21 (11): 2311-5
-
(2007)
Leukemia
, vol.21
, Issue.11
, pp. 2311-2315
-
-
Singer, J.B.1
Shou, Y.2
Giles, F.3
-
36
-
-
40349088802
-
Princeton (NJ)
-
US prescribing information, online, Available from URL:, Accessed 2007 Dec 6
-
Bristol-Myers Squibb: Princeton (NJ). Sprycel® (dasatinib): US prescribing information. [online]. Available from URL: http://www.fda.gov [Accessed 2007 Dec 6]
-
Sprycel® (dasatinib)
-
-
Bristol-Myers Squibb1
|